Wilson H. Miller
Jewish General Hospital · 608 works · 46,296 citations · h-index 82
Top works
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
- A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
- Role of the histone deacetylase complex in acute promyelocytic leukaemia
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
- Mechanisms of action of arsenic trioxide.
- Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.
- Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.
- Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial